To Evaluate the Efficacy and Safety of SR419 in Patients With Postherpetic Neuralgia (PHN)

NCT05357677 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

83

Enrollment

INDUSTRY

Sponsor class

Conditions

Postherpetic Neuralgia

Interventions

DRUG: SR419

Sponsor

Shanghai SIMR Biotechnology Co., Ltd.